Expansion of Clinical Trial Capacity in U.S. Communities
Backed by McKinsey, the Clinical Trials Access Collaborative (CTAC) has expanded clinical trial capacity at community research sites across the United States, enabling more than 20 new trials and enrolling over 4,600 participants so far.
Goals and Background
CTAC aims to broaden who can take part in medical research. The initiative—currently pursuing 501(c)(3) nonprofit status—evolved from an earlier grant and learning effort called Equitable Breakthroughs in Medicine Development (EQBMED).
Building a More Inclusive Research Ecosystem
The Collaborative links trial sponsors, health systems, community organizations, and the wider research ecosystem to accelerate participation in areas historically excluded from research. CTAC’s goal is to build a network of local clinical sites equipped with the tools and resources needed for sustained trial activity.
Addressing Disparities in Clinical Trial Access
Clinical trial access remains highly concentrated: roughly half of trials occur in just 2 percent of U.S. zip codes. McKinsey Senior Expert Tamara Baer, MD, notes that communities w...